Neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab improves pathological and DFS outcomes in MIBC

ASCO GU 2026: Updates in renal cancer

ASCO GU 2026: Updates in bladder cancer

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

The Vanessa Moss Prize: celebrating research into cancer health disparities

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies

Extreme heat exposure around diagnosis is linked to higher mortality in multiple myeloma

Global cancer burden, prevention, and inequalities across regions